Avatar
Yahoo News source @yahoo.com · Sunnyvale, California 🇺🇸· 3w

#NovoNordisk #FDA #DrugSafety

Link Preview
www.yahoo.com
FDA: Novo Nordisk failed to report deaths of weight-loss drug patients
Add Yahoo as a preferred source to see more of our stories on Google. The manufacturer of popular weight-loss drugs Ozempic and Wegovy, Novo Nordisk, is taking heat from the federal government for regularly failing to report potential side effects of its GLP-1 medications, including deaths.
Avatar
Aol News source @aol.com · New York City 🇺🇸· 3w

#NovoNordisk #GLP1Drugs #DrugSafety

Link Preview
www.aol.com
FDA: Novo Nordisk failed to report deaths of weight-loss drug patients
The manufacturer of popular weight-loss drugs Ozempic and Wegovy, Novo Nordisk, is taking heat from the federal government for regularly failing to report potential side effects of its GLP-1 medications, including deaths.
Avatar
Newsweek News source @newsweek.com · New York 🇺🇸· 3w

#Ozempic #NovoNordisk #Lawsuit

Link Preview
www.newsweek.com
Ozempic maker sued after woman died from stomach paralysis
The maker of Ozempic, Novo Nordisk, has been hit with a lawsuit over allegations of wrongful death after a woman using the drug died from gastroparesis, a condition also known as stomach paralysis.
Avatar
NBC News News source @nbcnews.com · Washington (state) 🇺🇸· 4w

#FDA #NovoNordisk #DrugSafety

Link Preview
www.nbcnews.com
FDA warns Novo Nordisk of potential unreported GLP-1 side effects
The Food and Drug Administration issued a warning letter to Novo Nordisk -- the maker of Ozempic and Wegovy -- for failing to report potential side effects in patients who took its blockbuster medications.
Avatar
CBS News News source @cbsnews.com · New York 🇺🇸· 4w

#FDA #Ozempic #NovoNordisk

Link Preview
www.cbsnews.com
FDA warns Novo Nordisk over unreported potential Ozempic side effects
Emily Mae Czachor is a reporter and news editor at CBSNews. com. She typically covers breaking news, extreme weather and issues involving social justice.
Avatar
CNBC News source @cnbc.com · New Jersey 🇺🇸· Feb 25

#NovoNordisk #Pharmaceuticals #Investing

Link Preview
www.cnbc.com
These 4 charts show the scale of Novo Nordisk's woes
Novo stock is down 75% since peaking at just over 1,000 Danish kroner a share in mid-2024, illustrating waning investor confidence.
Avatar
NBC News News source @nbcnews.com · Washington (state) 🇺🇸· Feb 24

#NovoNordisk #Healthcare #DiabetesTreatment

Link Preview
www.nbcnews.com
Novo Nordisk to halve U.S. list price of Wegovy from 2027
Novo Nordisk will slash U. S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year, the Danish drugmaker said on Tuesday.
Avatar
TechTarget News source @techtarget.com · Jan 5

#Wegovy #WeightLoss #NovoNordisk

Link Preview
www.techtarget.com
Novo's Wegovy pill hits the market with a $149 cash-pay price | Tec...
Novo Nordisk has launched oral Wegovy in the U. S. , with cash-pay pricing starting at $149 per month for the lowest doses and ranging up to $299 for higher doses.
F
The Motley Fool News source @fool.com · Jan 3

#Pharmaceuticals #NovoNordisk #HealthcareInvesting

Link Preview
www.fool.com
2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026
The pharmaceutical leader looks poised to stop the bleeding. Novo Nordisk's (NVO +2. 93%) shareholders must be happy to see 2025 finally come to a close.